Year: 2026

Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Written by Customer Service on March 27, 2026. Posted in Earnings Releases And Operating Results.

AUCATZYL® (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 and $74.3 million* for the full year of 2025 AUCATZYL® UK launch underway following successful National Institute for Health and Care Excellence (NICE) evaluation Autolus continues to expect full year 2026 AUCATZYL® net product revenue of $120 million to $135 million and shift to positive gross margin to occur in 2026 Independent real-world AUCATZYL® data from ROCCA consortium confirm high level of clinical activity with favorable safety profile Pivotal Phase 2 clinical trials with obe-cel in lupus nephritis and pediatric ALL enrolling; initial clinical data from BOBCAT Phase 1 trial in progressive MS anticipated by year-end 2026 Conference call to be held today at 08:30 am EDT/12:30 pm GMT: conference call participants should pre-register...

Legence Reports Fourth Quarter and Year End 2025 Financial Results

Written by Customer Service on March 27, 2026. Posted in Earnings Releases And Operating Results.

Record Quarterly Revenues of $737.6 Million, a 34.6% Increase from a Year Ago Quarterly Adjusted EBITDA (non-GAAP) Increased 53% from Prior Year1 Record Total Backlog and Awards of $3.7 Billion, 49% Increase from a Year Ago, with Robust Q4 Book-to-Bill of 1.9x Tuck-In Acquisition of Seattle Area-Based Engineering Firm Establish First Quarter 2026 Guidance for Revenue of $925 Million – $950 Million and Non-GAAP Adjusted EBITDA of $90 Million – $100 Million Raise Full Year 2026 Guidance for Revenue to $3.7 Billion – $3.9 Billion and Non-GAAP Adjusted EBITDA of $400 Million – $430 Million SAN JOSE, Calif., March 27, 2026 (GLOBE NEWSWIRE) — Legence Corp. (Nasdaq: LGN) (“Legence” or the “Company”) today reported financial results for the fourth quarter and year ended December 31, 2025. “Our fourth quarter 2025...

Satellos Reports 2025 Financial Results and Highlights Recent Company Progress

Written by Customer Service on March 27, 2026. Posted in Earnings Releases And Operating Results.

Completed a US$57.2 million equity financing; commenced trading on the Nasdaq Global Market under the ticker “MSLE” on Feb. 6, 2026Secured global regulatory clearances and initiated BASECAMP, a placebo-controlled Phase 2 clinical trial of SAT-3247 in boys aged 7 to less than 10 years living with Duchenne muscular dystrophy (“Duchenne” or “DMD”)Presented initial functional outcomes from 56 days of treatment in TRAILHEAD (follow-on trial to CL-101) at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, demonstrating that grip strength improvements observed in CL-101 were maintained or improved in TRAILHEAD over an aggregate period of 9 to 13 monthsReported proteomic data from CL-101 (28-day Phase 1b trial in adults with DMD) at MDA, showing reductions in established biomarkers of muscle degeneration...

Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Written by Customer Service on March 27, 2026. Posted in Earnings Releases And Operating Results.

Company evaluating potential acquisitions and in-licensing opportunities to drive next phase of strategic development Cash position of $76.3 million as of December 31, 2025 expected to fund current operating plan beyond 2027 DALLAS, March 27, 2026 (GLOBE NEWSWIRE) — Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its fourth quarter and full year 2025 financial results and provided a corporate update. Recent Highlights:In January 2026, Axion Bio, Inc., a wholly owned subsidiary of Instil, discontinued clinical development of AXN-2510 and entered into a termination agreement with ImmuneOnco Biopharmaceuticals (Shanghai) Inc. to terminate the license and collaboration agreement for AXN-2510 and AXN-27M. Following this decision, Instil...

BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting

Written by Customer Service on March 27, 2026. Posted in Earnings Releases And Operating Results.

sNDA submitted seeking approval of IGALMI® in the at-home (outpatient) setting for the treatment of acute agitation associated with bipolar disorders or schizophrenia sNDA submission timeline supports potential approval as early as year-end 2026 Advancing commercial and launch plans based on third-party market assessment NEW HAVEN, Conn., March 27, 2026 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today reported financial results for the fourth quarter and full-year 2025 and provided an update on its late-stage pipeline and commercial launch readiness plans. The Company submitted a supplemental New Drug Application (sNDA) in January to the U.S. Food and Drug Administration (FDA) seeking label...

Heimstaden 2026 Annual General Meeting

Written by Customer Service on March 27, 2026. Posted in Public Companies.

Heimstaden AB has today held its Annual General Meeting 2026 and resolved the following:Adoption of the financial statements for the year ending 31 December 2025 Adoption of the proposal for allocation of the Company’s results and payment of no dividends. Granted discharge from liability to the current Board Members, and the co-CEOs, for their management in 2025. Re-election of Ivar Tollefsen, John Giverholt, Bente Landsnes, and Fredrik Reinfeldt as Board Members. Adoption of the proposal for directors’ fees. Re-election of the registered auditing firm Ernst & Young Aktiebolag as external auditor, with Jonas Svensson as the auditor in charge.ContactFrederik Stentoft Berling, Media Relations, media@heimstaden.com Cody Nelson, Investor Relations, +47 948 94 196, ir@heimstaden.com AboutHeimstaden is a leading European residential...

ALSTOM S.A: Alstom to deliver Belgrade’s first metro: A historic leap in urban mobility and economic growth

Written by Customer Service on March 27, 2026. Posted in Public Companies.

Alstom will deliver a fully integrated, turnkey metro solution, including 32 Metropolis trains This flagship urban project valued at €915 million[1] will support Serbia’s long-term growth, connectivity and climate ambitions27 March 2026 – Alstom, a global leader in smart and sustainable mobility, has secured a €915 million turnkey contract to deliver Belgrade’s Metro Line 1, the first fully automated metro system in Serbia. This project, connecting in the first phase Makiško Polje to Karaburma will alleviate surface congestion and unlock Belgrade’s potential as a leading European capital city. By cutting directly through the city center, the first phase of Metro Line 1 will span 15 km and 15 stations, including 11 km of tunnels. This is a structural transformation: by moving a significant portion of the city’s transit underground,...

Form 8.3 – [IDOX PLC – 26 03 2026] – (CGWL)

Written by Customer Service on March 27, 2026. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree IDOX PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: IDOX PLC AS AN ASSOCIATE OF THE CANACCORD...

Checkpoint Partners Rates Lleida.net a Buy at 3.50 Euros per Share

Written by Customer Service on March 27, 2026. Posted in Public Companies.

Analyst report identifies a 60-70% discount to sector peers Madrid, March 27, 2026.- Checkpoint Partners has published an analyst report on Lleida.net (BME:LLN) (EPA:ALLLN) with a Buy recommendation and a target price of 3.50 euros per share on a 12-month horizon. The report, authored by analyst Guillermo Serrano, describes the company as the most anomalously valued stock in its sector. At 5.4x EV/EBITDA and 8.0x P/E on a 2026 forward basis, Lleida.net trades at discounts of 60-70% to comparable companies, according to the Checkpoint analysis. The report highlights that the company’s profitability margins are expanding and its capital requirements remain low, while generating a free cash flow yield of 18%. The analyst identifies Lleida.net’s registered electronic notification platform as a business protected by EU eIDAS regulation...

Dimensional Fund Advisors Ltd. : Form 8.3 – Consortium comprising LondonMetric Property plc and Schroder Real Estate Investment Trust Limited

Written by Customer Service on March 27, 2026. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.KEY INFORMATIONFull name of discloser: Dimensional Fund Advisors Ltd. whose parent is Dimensional Fund Advisors LP, and also on behalf their investment advisory affiliates (“Dimensional”). The Dimensional entities are investment advisors and Dimensional expressly disclaims beneficial ownership of the shares described in this form 8.3.Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form...

Year: 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals